Showing 15 posts of 123 posts found.


Mylan looks to muscle in on Allergan’s Botox territory

March 1, 2018
Sales and Marketing Botox, Mylan, Revance Therapeutics, biotech, drugs, epipen, pharma, pharmaceutical

Mylan announced, alongside its financials, that it had signed a global collaboration and licensing agreement with Revance Therapeutics to partner …

Allergan’s patent gamble fails

February 27, 2018
Manufacturing and Production, Medical Communications Allergan, Mylan, biotech, drugs, patent, pharma, pharmaceutical

Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review …


EMA committee recommends seven therapies from Roche, GSK, MSD and more

January 29, 2018
Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …


Mylan and Biocon biosimilar approval expands to Brazil

January 2, 2018
Manufacturing and Production, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, pharma, pharmaceutical

Since Mylan and Biocon managed to gain US FDA approval for its Herceptin (Trastuzumab) biosimilar, it has forged ahead in …


Mylan’s Ogivri becomes first and only FDA-approved Herceptin biosimilar

December 4, 2017
Sales and Marketing Biocon, Cancer, FDA, Herceptin, Mylan, Roche, biosimilar, pharma

The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …


FDA unveils guidelines to help generic medical device versions reach the market

November 28, 2017
Research and Development, Sales and Marketing FDA, Mylan, Scott Gottlieb, auto injector, auto-injector, epipen, pharma

The scandal surrounding Mylan’s price-hiking of its flagship EpiPen epinephrine auto-injector was the news of last summer, continuing to grab …


Mylan to withdraw from Tel Aviv Stock Exchange

November 13, 2017
Sales and Marketing Mylan, TASE, pharma

US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement …

Teva’s woes continue, as shares sink to 17-year low on Q3 results

November 2, 2017
Medical Communications Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Spare a thought for Kare Schultz, he agreed to take on the position of CEO at Teva at the start …

Allergan ready to take a loss by selling Teva shares

November 2, 2017
Sales and Marketing Allergan, Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million …

CEO and President implicated as price-fixing probe widens

November 1, 2017
Research and Development, Sales and Marketing Mylan, Teva, biotech, drugs, pharma, pharmaceutical

A group of states, 45 members-strong, has expanded its probe into the generics pharmaceutical industry by expanding its case to …

Sanofi launches patent infringement lawsuit against Mylan over diabetes pen

October 25, 2017
Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma

Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …


Mylan and Biocon Neulasta biosimilar knocked back by FDA

October 11, 2017
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical

Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …


Mylan receives shock approval of Teva blockbuster

October 5, 2017
Sales and Marketing Copaxone, Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Mylan had been knocked back by the FDA in its quest to have its generic version of Copaxone approved earlier …


Top Ten most popular articles on this week

September 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten

It’s Friday, and it’s time for another round up of the most popular articles on over the last seven …


Indivior reaches settlement with Mylan over patent dispute

September 25, 2017
Sales and Marketing Mylan, indivior, patent, pharma, pharmaceutical, suboxone

Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by …

Latest content